| Title |
Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab
|
|---|---|
| Published in |
Annals of Hematology, January 2015
|
| DOI | 10.1007/s00277-014-2288-5 |
| Pubmed ID | |
| Authors |
N. L. Berinstein, S. Bhella, N. M. Pennell, M. C. Cheung, K. R. Imrie, D. E. Spaner, V. Milliken, L. Zhang, K. Hewitt, A. Boudreau, M. D. Reis, A. Chesney, D. Good, Z. Ghorab, L. K. Hicks, E. Piliotis, R. Buckstein |
| Abstract |
Three sequential phase II trials were conducted with different immunotherapy approaches to enhance the outcome of autologous transplant (high-dose therapy and autologous stem cell transplantation (HDT/ASCT)) for recurrent follicular lymphoma. Seventy-three patients were enrolled from 1996 to 2009. Patients received HDT/ASCT combined with (1) interferon-α 3 MU/m(2) subcutaneously (SC) three times per week (TIW) for 2 years post-ASCT, (2) rituximab (R) 375 mg/m(2) for in vivo purging 3-5 days pre-stem cell collection and 2 × 4 weekly R at 2 and 6 months post-ASCT, respectively, or (3) three infusions of R pre-stem cell collection followed by 6× R weekly and interferon-α 3 MU/m(2) SC TIW. Although not statistically significant, progression-free survival (PFS) for patients who received rituximab was 56.4 and 49.1 % at 5 and 10 years compared to 36 and 21 % in those who did not receive rituximab. Molecular relapse post-HDT/ASCT was the strongest predictor of PFS in a multivariate analysis. Molecular relapse was coincident with or preceded clinical relapses in 84 % of patients who relapsed-median of 12 months (range 0-129 months). Adverse events included secondary malignancy, transformation to diffuse large B cell lymphoma, prolonged mostly asymptomatic hypogammaglobulinemia, and pulmonary fibrosis. The long-term toxicity profile must be considered when selecting patients for this treatment. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 43 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 18% |
| Student > Ph. D. Student | 6 | 14% |
| Student > Doctoral Student | 3 | 7% |
| Student > Postgraduate | 3 | 7% |
| Professor > Associate Professor | 3 | 7% |
| Other | 6 | 14% |
| Unknown | 15 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 43% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Nursing and Health Professions | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 16 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2015.
All research outputs
#14,208,760
of 22,778,347 outputs
Outputs from Annals of Hematology
#989
of 2,166 outputs
Outputs of similar age
#186,516
of 352,271 outputs
Outputs of similar age from Annals of Hematology
#12
of 23 outputs
Altmetric has tracked 22,778,347 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,166 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,271 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.